List view / Grid view
High-Throughput Screening (HTS)
article
Expert view: Optimising the hit-to-lead workflow
Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.
article
Machine learning approaches as tools to accelerate drug discovery
Computational methods based on machine learning approaches are being introduced increasingly widely to screen the large number of molecules that have never participated in the drug discovery process, but which might have significant drug development potential. This article considers the latest advances in machine learning as applied to drug discovery...
article
Expert view: Addressing the big challenges in drug screening
One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.
article
Hit To Lead In-Depth Focus 2017
In this In-Depth Focus we look at a pragmatic approach to hit validation following biochemical high-throughput screening as well as identification of hits and leads for human African trypanosomiasis.
whitepaper
Whitepaper: Advancing therapeutic antibody discovery with multiplexed screening
In this whitepaper, IntelliCyt Corporation describe how the iQue Screener is used to perform multiplexed screens for antibody binding to either cell surface or to circulating target antigens...
webinar
Advancing the discovery of immunotherapeutics with large scale multiplexed experiments
27 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the challenges faced with antibody screening and how the iQue Screener can give an evaluation of cell killing mechanism, screening for immune checkpoint inhibitors and more...
whitepaper
Application note: Multiplexed detection of mouse cytokines using QBeads and the iQue Screener
This application note illustrates the value of multiplexing, rapid sampling, and assay miniaturisation using QBeads on the iQue Screener...
whitepaper
Application note: A high-throughput, radioactivity-free assay for cell-mediated cytotoxicity
In this application note, IntelliCyt Corporation demonstrate a fast, efficient, radioactivity-free CMC assay with low sample input requirements, enabling miniaturisation to 384-well plates, using the iQue® Screener...
webinar
Evaluating immunotherapeutic approaches with large scale functional assays for immuno-oncology
22 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the need for robust high content tools for current immunotherapeutic approaches, and how IntelliCyt's iQue Screener PLUS can give functional efficacy of immuno-oncology therapies...
whitepaper
Application note: Application of MultiCyt QBeads for high throughput cytokine profiling in human peripheral blood mononuclear cells
In this application note IntelliCyt Corporation report on the development and validation of their family of MultiCyt QBeads for the detection of cytokines in a high-throughput screening application on the iQue Screener...
news
Charles River Laboratories announces updates to oncology business
Charles River Laboratories International, Inc. (NYSE: CRL) recently announced updates to its expanding oncology discovery business, including significant additions to its online Tumor Model Compendium...
article
GSK: A Lifetime in Fluorescence
GSK's top investigators explain why the data quality offered by Fluorescence lifetime detection technology for drug discovery applications is superior…
news
Daiichi Sankyo to collaborate on drugs for neglected tropical diseases
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
article
Fast-tracking the approach to drug discovery and development
Mundipharma EDO GmbH's Dr Thomas Mehrling talks through the benefits of streamlining the drug discovery and development process using the EDO model...
